CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.59
+0.05 (+3.25%)
At close: 4:00PM EDT

1.60 +0.01 (0.63%)
After hours: 4:03PM EDT

Stock chart is not supported by your current browser
Previous Close1.54
Open1.56
Bid1.52 x 3100
Ask1.68 x 1100
Day's Range1.54 - 1.68
52 Week Range1.30 - 6.60
Volume179,070
Avg. Volume471,957
Market Cap17.001M
Beta0.68
PE Ratio (TTM)N/A
EPS (TTM)-1.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
Trade prices are not sourced from all markets
  • GlobeNewswire9 hours ago

    ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

    EDISON, N.J., June 20, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus, ...

  • GlobeNewswire2 days ago

    ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates

    EDISON, N.J., June 18, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus, ...

  • GlobeNewswire7 days ago

    ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today, the initiation of the clinical development program of CRV431, pursuant to the acceptance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). With the FDA’s approval, ContraVir plans to begin a streamlined early clinical program of CRV431 to test the clinical safety and efficacy profile in healthy volunteers and HBV-infected patients in the United States.

  • GlobeNewswire8 days ago

    ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record

    ContraVir Pharmaceuticals, Inc. (CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), today issued a reminder to shareholders that the Record Date of its proposed rights offering is June 14, 2018. To be a shareholder of record, ownership of ContraVir stock must occur by market close of June 12, 2018 to account for settlement.

  • GlobeNewswire16 days ago

    ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    ContraVir Pharmaceuticals, Inc. (CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), today provided an informational update to stockholders regarding its rights offering and the key dates and terms relative to the offering. Stockholders are advised to ensure they complete their open market purchases of ContraVir common stock by 5:00 PM ET on Tuesday, June 12, 2018 to be considered a stockholder of record on Thursday, June 14, 2018. Holders of the Company’s warrants issued in October 2015, April 2016 and April 2017 are also invited to participate in the rights offering on the same terms as the stockholders.

  • GlobeNewswire21 days ago

    ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model

    ContraVir Pharmaceuticals Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today findings from a preclinical study of CRV431 indicating that the drug, a cyclophilin inhibitor, decreased the extent of fibrosis in an animal model by 46 percent compared to vehicle control. In the treatment of HBV infections, an important objective is the reduction of liver disease including fibrosis, cirrhosis and hepatocellular carcinoma (HCC).  Previously, studies of CRV431 have demonstrated its antiviral effects via the reduction of HBV DNA, surface antigen, and other viral markers.  In the recently completed preclinical study of CRV431, mice were administered streptozotocin, followed by a high fat diet that began at three weeks of age and continued for the duration of the study.

  • GlobeNewswire22 days ago

    ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study

    ContraVir Pharmaceuticals Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today new findings confirming that CRV431, a cyclophilin inhibitor, reduces the number and size of liver tumors in a hepatocellular carcinoma (HCC) mouse model. Data from the study indicate that CRV431 reduced the number of tumor nodules by 44% and reduced the overall tumor burden by 56% (composite score based on tumor number and size) compared to the vehicle control group (p=0.02). Importantly, 25% of CRV431-treated mice had no liver tumors at the end of the 10 week study, whereas all vehicle-treated mice had at least five tumors per liver.

  • GlobeNewswire23 days ago

    ContraVir Pharmaceuticals to Present at 2018 BIO International Convention

    EDISON, N.J., May 29, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus announced ...

  • GlobeNewswire27 days ago

    ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV) announced today, a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 8, effective May 25, 2018 (the “Effective Date”). The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the common stock following the reverse split will be 21234W 202.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™

    EDISON, N.J., April 12, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus ...

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board

    EDISON, N.J., April 09, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment ...

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress™

    EDISON, N.J., April 03, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus, ...

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Twenty-First Century Fox Inc (NASDAQ: FOXA ) stock ...

  • Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued?
    Simply Wall St.7 months ago

    Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued?

    ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...